标题:Progress in photodynamic therapy on tumors
作者:Tian YY;Wang LL;Wang W
作者机构:[Tian, YY;Wang, W] Shandong Univ, Inst Biochem & Mol Biol, Sch Med, Jinan 250100, Peoples R China;[Wang, LL] Shandong Univ
通讯作者:Tian, Y Y
通讯作者地址:[Tian, YY]Shandong Univ, Inst Biochem & Mol Biol, Sch Med, Jinan 250100, Peoples R China.
来源:Laser Physics: An International Journal devoted to Theoretical and Experimental Laser Research and Application
出版年:2008
卷:18
期:10
页码:1119-1123
DOI:10.1134/S1054660X08100010
关键词:5-AMINOLEVULINIC ACID;IN-VITRO;AMINOLEVULINIC ACID;PROTOPORPHYRIN-IX;CELL CARCINOMA;CANCER;PHOTOSENSITIZERS;PHOTOGEM(R);HYPERICIN;DERIVATIVES
摘要:Photodynamic therapy (PDT) is a promising treatment on neoplastic pathologic tissues, which involves the administration of a photosensitizing agent followed by the exposure of the tissue to visible nonthermal light. Light energy is captured and transferred to other molecules resulting in the formation of short-lived energetic species, which interact with biological systems and then produce tissue damage. Photosensitizer can be taken up selectively by tumor cells because of the upregulation of low-density lipoprotein receptor-mediated endocytosis and the acidic tumor environments. In recent years, the application of PDT in the treatment of malignant lesions has increased dramatically. The first health agency approval for PDT was granted for Photofrin in Canada in 1993, and, now, it is licensed in many countries for the treatment of cancers. Although Photofrin is the most commonly used photosensitizer, it has significant side effects. Therefore, major effort has been invested in the development of new sensitizers and, to this end, many photosensitizers have been described and some are now in clinical trials.
收录类别:EI;SCOPUS;SCIE
WOS核心被引频次:23
Scopus被引频次:23
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-52949122495&doi=10.1134%2fS1054660X08100010&partnerID=40&md5=7a2c5774672a06833d4e27aa354cd8ca
TOP